The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 25, 2019

Filed:

Sep. 10, 2015
Applicants:

Children's Medical Center Corporation, Boston, MA (US);

Beth Israel Deaconess Medical Center, Inc., Boston, MA (US);

Inventors:

Mark Puder, Medfield, MA (US);

Bruce R. Bistrian, Ipswich, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/202 (2006.01); A61K 9/107 (2006.01); A61K 35/60 (2006.01); A61K 9/00 (2006.01); A61K 8/06 (2006.01); A61K 49/00 (2006.01); A61Q 19/08 (2006.01); A61K 8/31 (2006.01); A61K 8/34 (2006.01); A61K 8/368 (2006.01); A61K 8/37 (2006.01); A61K 8/58 (2006.01); A61K 8/64 (2006.01); A61K 8/67 (2006.01); A61K 8/97 (2017.01); A23L 33/12 (2016.01); A23L 33/00 (2016.01); A23L 29/10 (2016.01);
U.S. Cl.
CPC ...
A61K 31/202 (2013.01); A23L 29/10 (2016.08); A23L 33/12 (2016.08); A23L 33/30 (2016.08); A23L 33/40 (2016.08); A61K 8/062 (2013.01); A61K 8/31 (2013.01); A61K 8/342 (2013.01); A61K 8/345 (2013.01); A61K 8/368 (2013.01); A61K 8/37 (2013.01); A61K 8/585 (2013.01); A61K 8/64 (2013.01); A61K 8/67 (2013.01); A61K 8/97 (2013.01); A61K 9/0029 (2013.01); A61K 9/107 (2013.01); A61K 35/60 (2013.01); A61K 49/0006 (2013.01); A61Q 19/08 (2013.01); A23V 2002/00 (2013.01); A61K 2800/20 (2013.01); A61K 2800/48 (2013.01); A61K 2800/884 (2013.01);
Abstract

Disclosed herein is a formulation that can take the form of an emulsion which contains total enteral or parenteral nutrition for a recipient subject. The formulation includes as the sole fat components: (i) medium chain triglycerides; and (ii) very long chain fatty acids selected from (a) very long chain omega-3 polyunsaturated fatty acids; and (b) docosahexaenoic acid and arachidonic acid in a ratio of about 10:1 (v/v or w/w) to about 2000:1 (v/v or w/w). The sole fat components provide about 10% to about 90% total calories of the formulation, and the medium chain triglycerides provide about 25%-95% total fat calories of the formulation. Methods and kits for utilizing the formulation and for treating various disorders and diseases that involve an inflammatory response are also disclosed.


Find Patent Forward Citations

Loading…